Nasdaq: INSM

Insmed

Insmed biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. We are focused on the development and commercialization of novel, targeted inhaled therapies for patients with high unmet need battling orphan lung diseases.

Our lead product candidate, ARIKACE (liposomal amikacin for inhalation), is designed to treat rare lung infections in patients who have limited alternatives for treatment. ARIKACE is a differentiated, inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.